0001354457-24-000306.txt : 20240425
0001354457-24-000306.hdr.sgml : 20240425
20240425091050
ACCESSION NUMBER: 0001354457-24-000306
CONFORMED SUBMISSION TYPE: 25-NSE
CONFIRMING COPY:
PUBLIC DOCUMENT COUNT: 2
FILED AS OF DATE: 20240425
DATE AS OF CHANGE: 20240425
SUBJECT COMPANY:
COMPANY DATA:
COMPANY CONFORMED NAME: Acorda Therapeutics, Inc.
CENTRAL INDEX KEY: 0001008848
STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
ORGANIZATION NAME: 03 Life Sciences
IRS NUMBER: 133831168
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
FILING VALUES:
FORM TYPE: 25-NSE
SEC ACT: 1934 Act
SEC FILE NUMBER: 000-50513
BUSINESS ADDRESS:
STREET 1: TWO BLUE HILL PLAZA
CITY: PEARL RIVER
STATE: NY
ZIP: 10965
BUSINESS PHONE: 914-347-4300
MAIL ADDRESS:
STREET 1: TWO BLUE HILL PLAZA
CITY: PEARL RIVER
STATE: NY
ZIP: 10965
FORMER COMPANY:
FORMER CONFORMED NAME: ACORDA THERAPEUTICS INC
DATE OF NAME CHANGE: 19960222
FILED BY:
COMPANY DATA:
COMPANY CONFORMED NAME: Nasdaq Stock Market LLC
CENTRAL INDEX KEY: 0001354457
ORGANIZATION NAME:
IRS NUMBER: 521165937
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
FILING VALUES:
FORM TYPE: 25-NSE
BUSINESS ADDRESS:
STREET 1: One Liberty Plaza
CITY: New York
STATE: NY
ZIP: 10006
BUSINESS PHONE: 301-978-4144
MAIL ADDRESS:
STREET 1: Office of General Counsel
STREET 2: 805 King Farm Blvd.
CITY: ROCKVILLE
STATE: MD
ZIP: 20850
FORMER COMPANY:
FORMER CONFORMED NAME: The Nasdaq Stock Market LLC
DATE OF NAME CHANGE: 20060224
25-NSE
1
primary_doc.xml
X0203
0001354457
Nasdaq Stock Market LLC
0001008848
Acorda Therapeutics, Inc.
000-50513
15 Skyline Drive
Hawthorne
NY
NEW YORK
10532
1 914 347-4300
Common stock
17 CFR 240.12d2-2(b)
Aravind Menon
Hearings Advisor
2024-04-25
EX-99.25
2
acordelistreason.txt
Delisting Determination, The Nasdaq Stock Market, LLC, April 25, 2024,
Acorda Therapeutics, Inc.
The Nasdaq Stock Market LLC (the Exchange) has determined to remove
from listing the securities of Acorda Therapeutics, Inc., effective
at the opening of the trading session on May 6, 2024.
Based on review of information provided by the Company, Nasdaq Staff
determined that the Company no longer qualified for listing on the
Exchange pursuant to Listing Rules 5101, 5110(b), IM-5101-1, and
5550(b)(1).
The Company was notified of the Staff determination on April 3,
2024. The Company did not appeal the Staff determination to the
Hearings Panel. The Company securities were suspended on April 12,
2024. The Staff determination to delist the Company securities
became final on April 12, 2024.